Tislelizumab in patients with unresectable HCC demonstrates durable responses

(2:58)

Results of Phase II study of tislelizumab in R/R NK/T-cell neoplasms

(1:15)

Tislelizumab in First-Line Treatment for Advanced Gastric Cancer #oncology #pencis #lecture #AntiPD1

(31)

Tislelizumab in oesophageal cancer after systemic therapy

(7:47)

RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC

(3:14)

Sitravatinib + tislelizumab in advanced BTC after systemic treatment failure: Phase II study

(1:48)

RATIONALE-306: tislelizumab and chemotherapy in ESCC

(4:3)

QoL analyses from RATIONALE-301 of tislelizumab vs sorafenib in HCC

(2:1econd)

Tislelizumab Plus Zanubrutinib for Richter’s Transformation - Dr. Barbara Eichhorst ASH 2023

(9:38)

RATIONALE-305: tislelizumab + chemo vs placebo +chemo in advanced GC/GEJC

(27)

AdvanTIG-202: tislelizumab +/- ociperlimab in recurrent/metastatic cervical cancer

(3:48)

Tislelizumab OS benefit vs sorafenib as first line treatment for unresectable hepatocellular car...

(3:12)

DisTinGuish: DKN-01 with tislelizumab and chemotherapy in GC/GEJC

(2:16)

Tislelizumab

(1:9)

RATIONALE-306: Asian subgroup of 1L tislelizumab + chemo vs chemo alone for esophageal SCC

(3:9)

Tislelizumab Approved as Second-Line Treatment for Advanced, Metastatic Esophageal Cancer

(5:5)

Chapter 22. Tislelizumab

(7:)

Novel PD-1 inhibitor and BTK inhibitor combination: tislelizumab and zanubrutinib

(57)

Tislelizumab for R/R classical Hodgkin lymphoma

(2:42)

Cancer immunotherapy | The PD-L1 pathway

(2:12)